J
50.82
0.62 (1.24%)
| Penutupan Terdahulu | 50.20 |
| Buka | 50.29 |
| Jumlah Dagangan | 563,777 |
| Purata Dagangan (3B) | 589,019 |
| Modal Pasaran | 2,650,999,808 |
| Harga / Jualan (P/S) | 177.44 |
| Harga / Buku (P/B) | 3.61 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 Aug 2024 |
| Margin Operasi (TTM) | -8,164.46% |
| EPS Cair (TTM) | -1.17 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -82.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3.57% |
| Nisbah Semasa (MRQ) | 38.80 |
| Aliran Tunai Operasi (OCF TTM) | -36.99 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -21.56 M |
| Pulangan Atas Aset (ROA TTM) | -9.93% |
| Pulangan Atas Ekuiti (ROE TTM) | -12.05% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Janux Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
0.3
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.30 |
|
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 7.33% |
| % Dimiliki oleh Institusi | 95.96% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 115.00 (Stifel, 126.29%) | Beli |
| Median | 80.50 (58.40%) | |
| Rendah | 62.00 (Scotiabank, 22.00%) | Pegang |
| Purata | 84.50 (66.27%) | |
| Jumlah | 5 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 44.71 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Scotiabank | 04 Dec 2024 | 62.00 (22.00%) | Pegang | 40.18 |
| HC Wainwright & Co. | 03 Dec 2024 | 70.00 (37.74%) | Beli | 40.18 |
| 07 Nov 2024 | 63.00 (23.97%) | Beli | 54.21 | |
| Leerink Partners | 03 Dec 2024 | 91.00 (79.06%) | Beli | 40.18 |
| 22 Nov 2024 | 79.00 (55.45%) | Beli | 50.31 | |
| Stifel | 03 Dec 2024 | 115.00 (126.29%) | Beli | 40.18 |
| 06 Sep 2024 | 70.00 (37.74%) | Beli | 41.26 | |
| Cantor Fitzgerald | 07 Nov 2024 | 100.00 (96.77%) | Beli | 54.21 |
| 16 Sep 2024 | 100.00 (96.77%) | Beli | 49.89 | |
| UBS | 24 Oct 2024 | 69.00 (35.77%) | Beli | 53.31 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| CAMPBELL DAVID ALAN | - | 48.82 | -25,000 | -1,220,500 |
| Jumlah Keseluruhan Kuantiti Bersih | -25,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -1,220,500 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 48.82 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| CAMPBELL DAVID ALAN | Pegawai | 25 Nov 2024 | Jual automatik (-) | 25,000 | 48.82 | 1,220,500 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |